Cargando…

Structure-guided discovery of a single-domain antibody agonist against human apelin receptor

Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chronic heart failure. Here, we report the structure-guided discovery of a single-domain antibody (sdAb) agonist JN241-9, based on the cocrystal structure of APJ with an sd...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yanbin, Ding, Yao, Song, Xianqiang, Ma, Xiaochuan, Li, Xun, Zhang, Ning, Song, Yunpeng, Sun, Yaping, Shen, Yuqing, Zhong, Wenge, Hu, Liaoyuan A., Ma, Yingli, Zhang, Mei-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962038/
https://www.ncbi.nlm.nih.gov/pubmed/31998837
http://dx.doi.org/10.1126/sciadv.aax7379
Descripción
Sumario:Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chronic heart failure. Here, we report the structure-guided discovery of a single-domain antibody (sdAb) agonist JN241-9, based on the cocrystal structure of APJ with an sdAb antagonist JN241, the first cocrystal structure of a class A G protein–coupled receptor (GPCR) with a functional antibody. As revealed by the structure, JN241 binds to the extracellular side of APJ, makes critical contacts with the second extracellular loop, and inserts the CDR3 into the ligand-binding pocket. We converted JN241 into a full agonist JN241-9 by inserting a tyrosine into the CDR3. Modeling and molecular dynamics simulation shed light on JN241-9–stimulated receptor activation, providing structural insights for finding agonistic antibodies against class A GPCRs.